Estimating the costs of caring for people with Alzheimer disease in California: 2000-2040
- PMID: 11382092
Estimating the costs of caring for people with Alzheimer disease in California: 2000-2040
Abstract
The costs of caring for people with Alzheimer disease (AD) in California are estimated using data from a study of the costs of caring for community-resident and institutionalized people with AD, combined will prevalence and population projections. Costs for community-resident patients will increase 83 percent in the period 2000 ($23.4 billion) to 2020 ($42.8 billion), and will grow an additional 59 percent from 2020 to 2040 ($68.1 billion). Costs for AD patients in institutions will increase 84 percent from 2000 ($2.5 billion) to 2020 ($4.6 billion), and will grow an additional 61 percent from 2020 to 2040 ($7.4 billion), assuming the supply of nursing home beds meets projected demand. Total costs of caring for AD patients will nearly triple between 2000 and 2040. The rapid aging of the U.S. population makes more aggressive societal action necessary if the personal and societal burden of Alzheimer's disease is to be reduced in the future.
Similar articles
-
Economic considerations in Alzheimer's disease.Pharmacotherapy. 1998 Mar-Apr;18(2 Pt 2):68-73; discussion 79-82. Pharmacotherapy. 1998. PMID: 9543467 Review.
-
Alzheimer's disease and managed care: a convincing case for action.Manag Care Interface. 2007 Mar;20(3):26-7. Manag Care Interface. 2007. PMID: 17458478
-
The cost of Alzheimer's disease in managed care: a cross-sectional study.Am J Manag Care. 1999 Jul;5(7):867-77. Am J Manag Care. 1999. PMID: 10557408
-
2009 Alzheimer's disease facts and figures.Alzheimers Dement. 2009 May;5(3):234-70. doi: 10.1016/j.jalz.2009.03.001. Alzheimers Dement. 2009. PMID: 19426951
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
Cited by
-
A Review of the Current Mammalian Models of Alzheimer's Disease and Challenges That Need to Be Overcome.Int J Mol Sci. 2021 Dec 6;22(23):13168. doi: 10.3390/ijms222313168. Int J Mol Sci. 2021. PMID: 34884970 Free PMC article. Review.
-
A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.Pharmacoeconomics. 2011 Feb;29(2):141-56. doi: 10.2165/11539450-000000000-00000. Pharmacoeconomics. 2011. PMID: 21090840
-
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.CNS Drugs. 2006;20(5):411-7. doi: 10.2165/00023210-200620050-00005. CNS Drugs. 2006. PMID: 16696580 Clinical Trial.
-
Alzheimer's disease: is pacemaker implantation safe?Am J Alzheimers Dis Other Demen. 2012 May;27(3):202-5. doi: 10.1177/1533317512444457. Epub 2012 Apr 20. Am J Alzheimers Dis Other Demen. 2012. PMID: 22523108 Free PMC article. Clinical Trial.
-
Contrary to stereotypes, a nursing home resident radiates dignity and joy.Am J Public Health. 2006 Jul;96(7):1163. doi: 10.2105/AJPH.2006.090506. Epub 2006 May 30. Am J Public Health. 2006. PMID: 16735609 Free PMC article. No abstract available.